Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05428033
PHASE3

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

View on ClinicalTrials.gov

Summary

This trial will be conducted to evaluate the efficacy of centanafadine once daily (QD) extended release (XR) versus placebo in the treatment of child subjects (4 to 12 years, inclusive) with ADHD. The trial will consist of a screening period, a double-blind treatment period, and follow-up period.

Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Efficacy and Safety of Once Daily Centanafadine Capsules for the Treatment of Children With Attention-deficit/Hyperactivity Disorder (ADHD)

Key Details

Gender

All

Age Range

4 Years - 12 Years

Study Type

INTERVENTIONAL

Enrollment

574

Start Date

2022-07-11

Completion Date

2025-03-17

Last Updated

2026-04-13

Healthy Volunteers

No

Interventions

DRUG

centanafadine capsule

capsule

OTHER

placebo capsule

capsule

Locations (1)

For additional information regarding sites, contact 844-687-8522

New York, New York, United States